| Autor: |
de Eusebio E; Sección de Dermatología, Hospital Universitario de Guadalajara, Guadalajara, Spain., Armario-Hita JC, de Miquel VA |
| Jazyk: |
angličtina |
| Zdroj: |
American journal of clinical dermatology [Am J Clin Dermatol] 2014 Feb; Vol. 15 Suppl 1, pp. S5-16. |
| DOI: |
10.1007/s40257-013-0054-4 |
| Abstrakt: |
Psoriasis is a disabling chronic inflammatory condition of the skin and joints that typically requires long-term treatment. Recommended treatments for psoriasis include a wide range of topical and systemic options, from topical agents and targeted phototherapy for mild psoriasis to traditional systemic agents such as methotrexate, cyclosporine and acitretin for more serious disease. The introduction of targeted biological agents such as T-cell-modulating agents, tumor necrosis factor α (TNFα) antagonists and interleukin (IL)-12 and IL-23 inhibitors has provided new choices for the management of psoriasis and psoriatic arthritis that may offer better long-term efficacy and tolerability than traditional approaches. Most biological agents are administered by subcutaneous injection. Infliximab, a TNFα antagonist, is the only biological agent approved for psoriasis that is administered by intravenous infusion, in the setting of hospital-based or specialized infusion center-based clinics. Infliximab allows weight-based dosing and may offer more rapid disease control than other biological agents, with significant improvements seen as early as 1 week after treatment initiation. This article gives an overview of psoriasis management, focusing on clinic-based infusion therapy with infliximab. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
